Antiphospholipid antibodies: Lessons from the bench

Journal of Autoimmunity

Volumn 28, Issue 2-3, 2007, Pages 129-133

  Koike, Takao ^a   Bohgaki, Miyuki ^a   Amengual, Olga ^a   Atsumi, Tatsuya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiphospholipid antibodies; Autoantibodies; Inflammation; Phospholipid antibody syndrome; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUPUS ANTICOAGULANT; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CLINICAL FEATURE; HEMOLYTIC ANEMIA; HUMAN; LIVEDO RETICULARIS; MENTAL DISEASE; NEUROLOGIC DISEASE; PATHOGENESIS; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; SKIN ULCER; THROMBOCYTOPENIA; THROMBOSIS; VALVULAR HEART DISEASE;

ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; THROMBOSIS;

EID: 34247577467     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2007.02.009     Document Type: Review

References (64)

1. Khamashta M.A. Hughes syndrome: history. In: Khamashta M.A. (Ed). Hughes Syndrome: antiphospholipid syndrome (2006), Springer-Verlag, London 3-8
2. Schorer A.E., Wickham N.W., and Watson K.V. Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial prostacyclin release and platelet aggregation. Br J Haematol 71 (1989) 399-407
3. Reverter J.C., Tassies D., Font J., Khamashta M.A., Ichikawa K., Cervera R., et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 41 (1998) 1420-1427
4. Ames P.R., Tommasino C., Iannaccone L., Brillante M., Cimino R., and Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idopathic antiphospholipid antibodies - a crucial role for acquired free protein S deficiency. Thromb Haemost 76 (1996) 190-194
5. Oosting J.D., Derksen R.H.W.M., Bobbink I.W.G., Hackeng T.M., Bouma B.N., and de Groot P.G. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood 81 (1993) 2618-2625
6. Kornberg A., Blank M., Kaufman S., and Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 153 (1994) 1328-1332
7. Amengual O., Atsumi T., Khamashta M.A., and Hughes G.R.V. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 79 (1998) 276-281
8. Tannenbaum S.H., Finko R., and Cines D.B. Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 137 (1986) 1532-1537
9. Branch D.W., and Rodgers G.M. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 168 (1993) 206-210
10. Harris E.N., Gharavi A.E., Boey M.L., Patel B.M., Mackworth-Young C.G., Loizou S., et al. Anti-cardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet ii (1983) 1211-1214
11. Koike T., Sueishi M., Funaki H., Tomioka H., and Yoshida S. Antiphospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol 56 (1984) 193-199
12. Brey R.L., Abbott R.D., Curb J.D., et al. Beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke 32 (2001) 1701-1706
13. Nojima J., Kuratsune H., Suehisa E., Kitani T., Iwatani Y., and Kanakura Y. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies - co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 91 (2004) 967-976
14. Lopez L.R., Dier K.J., Lopez D., Merrill J.T., and Fink C.A. Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 121 (2004) 142-149
15. Galli M., Luciani D., Bertolini G., and Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102 (2003) 2717-2723
16. Galli M., Comfurius P., Maassen C., Hemker H.C., de Baets M.H., van Breda-Vriesman P.J., et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335 (1990) 952-953
17. McNeil H.P., Simpson R.J., Chesterman C.N., and Krilis S.A. Anti-phospholipid antibodies are directed against a complex antigen that induces a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87 (1990) 4120-4124
18. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., and Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336 (1990) 177-178
19. Koike T., and Matsuura E. What is the "true" antigen for anticardiolipin antibodies?. Lancet 337 (1991) 671-672
20. Roubey R.A.S. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 39 (1996) 1444-1454
21. Sheng Y., Kandiah D.A., and Krilis S.A. Anti-β2-glycoprotein I autoantibodies from patients with the "antiphospholipid" syndrome bind to β2-glycoprotein I with low affinity: dimerization of β2-glycoprotein I induces a significant increase in anti-β2-glycoprotein I antibody affinity. J Immunol 161 (1998) 2038-2043
22. Matsuura E., Igarashi Y., Yasuda T., Triplett D.A., and Koike T. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 179 (1994) 457-462
23. Tsutsumi A., Ichikawa K., Matsuura E., Sawada K., and Koike T. Heterogeneous behavior of anti-β2-glycoprotein I antibodies on various commercially available enzyme immunoassay plates coated with β2-glycoprotein I. J Rheumatol 27 (2000) 391-396
24. Chamley L.W., Duncalf A.M., Konarkowska B., Mitchell M.D., and Johnson P.M. Conformationally altered β2-glycoprotein I is the antigen for anti-cardiolipin autoantibodies. Clin Exp Immunol 115 (1999) 571-576
25. Galazka M., Tang M., DeBari V.A., et al. Modification of β2glycoprotein I by glutardialdehyde. Conformational changes and aggregation accompany exposure of the cryptic autoepitope. Appl Biochem Biotechnol 76 (1999) 1-13
26. Igarashi M., Matsuura E., Igarashi Y., et al. Human β2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a Baculovirus system. Blood 87 (1996) 3262-3270
27. Wang M.X., Kandiah D.A., Ichikawa K., et al. Epitope specificity of monoclonal anti β2-glycoprotien I antibodies derived from patients with the antiphospholipid syndrome. J Immunol 155 (1995) 1629-1636
28. George J., Gilburd B., Hojnik M., Levy Y., Langevitz P., Matsuura E., et al. Target recognition of β2-glycoprotein I (β2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of β2GPI in antibody binding. J Immunol 150 (1998) 3917-3923
29. Iverson G.M., Victoria E.J., and Marquis D.M. Anti-β2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI. Proc Natl Acad Sci USA 95 (1998) 15542-15546
30. Koike T., Ichikawa K., Atsumi T., Kasahara H., and Matsuura E. β2-glycoprotein I-anti-β2-glycoprotein I interaction. J Autoimmun 15 (2000) 97-100
31. de Laat B., Derksen R.H., Urbanus R.T., and de Groot P.G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105 (2005) 1540-1545
32. de Laat B., Derksen R.H., van Lummel M., Pennings M.T., and de Groot P.G. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 107 (2006) 1916-1924
33. Kasahara H., Matsuura E., Kaihara K., Yamamoto D., Kobayashi K., Inagaki J., et al. Antigenic structures recognized by anti-beta2-glycoprotein I auto-antibodies. Int Immunol 17 (2005) 1533-1542
34. Mann K. Biochemistry and physiology of blood coagulation. Thromb Haemost 82 (1999) 165-174
35. Mackman N. Regulation of the tissue factor gene. Faseb J 9 (1995) 883-889
36. Amengual O., Atsumi T., Khamashta M.A., and Hughes G.R. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 79 (1998) 276-281
37. Atsumi T., Khamashta M.A., Amengual O., and Hughes G.R. Up-regulated tissue factor expression in antiphospholipid syndrome. Thromb Haemost 77 (1997) 222-223
38. Cuadrado M.J., Lopez-Pedrera C., Khamashta M.A., Camps M.T., Tinahones F., Torres A., et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 40 (1997) 834-841
39. Oosting J., Derksen R., Blokzijl L., Sixma J., and de Groot P.G. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity: studies in a thrombosis model. Thromb Haemost 68 (1992) 278-284
40. Branch D., and Rodgers G. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 168 (1993) 206-210
41. Schved J., Gris J., Ollivier V., Wautier J., Tobelem G., and Caen J. Procoagulant activity of endotoxin or tumor necrosis factor activated monocytes is enhanced by IgG from patients with lupus anticoagulant. Am J Hematol 41 (1992) 92-96
42. Martini F., Farsi A., Gori A.M., Boddi M., Fedi S., Domeneghetti M.P., et al. Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. Lupus 5 (1996) 206-211
43. Zhou H., Wolberg A.S., and Roubey R.A. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 104 (2004) 2353-2358
44. Reverter J.C., Tassies D., Font J., Khamashta M.A., Ichikawa K., Cervera R., et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 41 (1998) 1420-1427
45. Del Papa N., Guidali L., Spatola L., Bonara P., Borghi M.O., Tincani A., et al. Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol 13 (1995) 179-185
46. Del Papa N., Guidali L., Sala A., Buccellati C., Khamashta M.A., Ichikawa K., et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 40 (1997) 551-561
47. Del Papa N., Sheng Y.H., Raschi E., Kandiah D.A., Tincani A., Khamashta M.A., et al. Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. J Immunol 160 (1998) 5572-5578
48. Del Papa N., Meroni P.L., Barcellini W., Sinico A., Radice A., Tincani A., et al. Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. Clin Immunol Immunopathol 63 (1992) 267-274
49. Simantov R., LaSala J.M., Lo S.K., Gharavi A.E., Sammaritano L.R., Salmon J.E., et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 96 (1995) 2211-2219
50. Pierangeli S.S., Colden-Stanfield M., Liu X., Barker J.H., Anderson G.L., and Harris E.N. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 99 (1999) 1997-2002
51. Vega-Ostertag M., Harris E.N., and Pierangeli S.S. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 50 (2004) 2911-2919
52. Bohgaki M., Atsumi T., Yamashita Y., Yasuda S., Sakai Y., Furusaki A., et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol 16 (2004) 1633-1641
53. Pierangeli S.S., Vega-Ostertag M., and Harris E.N. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res 114 (2004) 467-476
54. Dunoyer-Geindre S., de Moerloose P., Galve-de Rochemonteix B., Reber G., and Kruithof E.K. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost 88 (2002) 851-857
55. Saccani S., Pantano S., and Natoli G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol 3 (2002) 69-75
56. McGilvray I.D., Tsai V., Marshall J.C., Dackiw A.P., and Rotstein O.D. Monocyte adhesion and transmigration induce tissue factor expression: role of the mitogen-activated protein kinases. Shock 18 (2002) 51-57
57. Ohsawa M., Koyama T., Nara N., and Hirosawa S. Induction of tissue factor expression in human monocytic cells by protease inhibitors through activating activator protein-1 (AP-1) with phosphorylation of Jun-N-terminal kinase and p38. Thromb Res 112 (2003) 313-320
58. Blum S., Issbrucker K., Willuweit A., Hehlgans S., Lucerna M., Mechtcheriakova D., et al. An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J Biol Chem 276 (2001) 33428-33434
59. Eto M., Kozai T., Cosentino F., Joch H., and Luscher T.F. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105 (2002) 1756-1759
60. Herkert O., Diebold I., Brandes R.P., Hess J., Busse R., and Gorlach A. NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells. Circulation 105 (2002) 2030-2036
61. Lopez-Pedrera C., Buendia P., Cuadrado M.J., Siendones E., Aguirre M.A., Barbarroja N., et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocytes tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK1/ERK pathway. Arthritis Rheum 54 (2006) 301-311
62. Ma K., Simantov R., Zhang J.C., Silverstein R., Hajjar K.A., and McCrae K.R. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 275 (2000) 15541-15548
63. Raschi E., Testoni C., Bosisio D., Borghi M.O., Koike T., Mantovani A., et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 101 (2003) 3495-3500
64. Lutters B.C., Derksen R.H., Tekelenburg W.L., Lenting P.J., Arnout J., and de Groot P.G. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 278 (2003) 33831-33838